Explore

Rapid Read Rapid Read
Scripps Research Develops Nanodisc Technology to Enhance Vaccine Design Against HIV and Ebola

Scripps Research Develops Nanodisc Technology to Enhance Vaccine Design Against HIV and Ebola

Researchers at Scripps Research, in collaboration with IAVI, have developed a new platform using nanodisc technology to study viral proteins in a more natural form. This method places proteins into lipid-based particles, mimicking the virus's outer membrane, which helps preserve the proteins' natural structure and behavior. The study, published in Nature Communications, tested this platform with proteins from HIV and Ebola, which have been challenging for vaccine development due to their complex surface proteins. The new approach offers a clearer view of how antibodies interact with viruses, potentially guiding future vaccine design.
Rapid Read Rapid Read
Israeli Researcher Explores Reversible Aging and Disease Prevention

Israeli Researcher Explores Reversible Aging and Disease Prevention

Prof. Debbie Toiber, a molecular biologist at Ben-Gurion University of the Negev, is conducting research to understand the mechanisms of aging and prevent age-related diseases. Her work focuses on neurodegenerative diseases such as Alzheimer's and Parkinson's, aiming to identify early disruptions in cellular processes that lead to pathological aging. By studying animal models and human cells, Toiber seeks to detect decision points where cells choose between healthy and pathological aging. Her research involves using chemical reactions and stem cell technology to study brain cells, with the goal of steering them towards healthier aging trajectories.
Rapid Read Rapid Read
University of Colorado Researchers Develop Experimental Drug to Reverse Osteoarthritis in Animals

University of Colorado Researchers Develop Experimental Drug to Reverse Osteoarthritis in Animals

Researchers at the University of Colorado (UC) Boulder have developed an experimental drug that has shown the potential to reverse osteoarthritis in animal models. Led by chemical and biological engineer Stephanie Bryant, the team has created a slow-release drug-delivery system that, when injected into damaged joints, encourages the body's own cartilage and bone cells to repair the damage. This development marks a significant step forward in osteoarthritis treatment, as current options are limited to pain management or joint replacement. The research, which is not yet peer-reviewed, aims to move into phase two, focusing on safety and toxicology, to lay the groundwork for human clinical trials. The team is also working on an injectable 'implant' to recruit the body's cells to repair cartilage gaps, offering potential solutions for different stages of osteoarthritis.
Rapid Read Rapid Read
Researchers Develop Injectable Hydrogel for Improved Surgical Sealant

Researchers Develop Injectable Hydrogel for Improved Surgical Sealant

A new injectable thixotropic hydrogel has been developed to address the issue of anastomotic leakage in gastrointestinal surgery. This hydrogel, composed of elastin-like polypeptide and oxidized dextran, offers a ready-to-use solution that solidifies upon contact with tissue, eliminating the need for intraoperative mixing required by conventional sealants like fibrin glue. The hydrogel demonstrates reversible sol-gel transitions and shear-responsive behavior, with the most oxidized formulation showing significant recovery of storage modulus after high strain. It exhibits adhesive strength and burst pressure comparable to fibrin glue, as demonstrated in lap-shear tests on porcine small intestine. In vivo experiments in mice showed the hydrogel's localization at the injection site for up to a week, with mild serosal thickening and no severe inflammation, indicating favorable physiological stability.
Rapid Read Rapid Read
Salk Institute Secures $41.3M Funding to Advance Sonogenetics Therapies for Peripheral Neuropathies

Salk Institute Secures $41.3M Funding to Advance Sonogenetics Therapies for Peripheral Neuropathies

The Salk Institute for Biological Studies has received $41.3 million in federal funding from the Advanced Research Projects Agency for Health (ARPA-H) to advance sonogenetics therapies. Sonogenetics involves using low-intensity ultrasound to control cellular proteins noninvasively. The funding will support the development of biological tools and ultrasound delivery systems, aiming to move sonogenetics into human clinical trials. The initial focus is on treating peripheral neuropathies, with potential applications for other conditions. Sreekanth Chalasani, PhD, leads the project, which includes collaborations with multiple institutions such as Scripps Research and Duke University. The initiative aims to create a drug-free therapy platform using engineered ultrasound-sensitive proteins paired with wearable ultrasound technology.
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Rapid Read Rapid Read
Israeli Researchers Advance 3D Bioprinting for Organ Transplants

Israeli Researchers Advance 3D Bioprinting for Organ Transplants

At Rambam Medical Center in Haifa, Israeli researchers are making strides in 3D bioprinting, creating living lung tissue from human cells. Led by Dr. Arbel Artzy-Schnirman, the team is developing technology that could revolutionize organ transplants, drug testing, and personalized medicine. While full organ printing remains a distant goal, the ability to print functional tissue fragments marks a significant step forward. The research aims to address organ shortages and improve drug development by creating accurate human tissue models for testing.
Rapid Read Rapid Read
Stanford Report Reveals Growing Disconnect Between AI Experts and Public Sentiment

Stanford Report Reveals Growing Disconnect Between AI Experts and Public Sentiment

Stanford University's annual report on the AI industry highlights a significant divergence between AI experts and public sentiment regarding the impact of artificial intelligence. The report notes that while AI experts are optimistic about the technology's potential benefits, the general public remains skeptical, particularly concerning its effects on jobs, medical care, and the economy. According to the report, only 10% of Americans express excitement about AI's increasing role in daily life, compared to 56% of AI experts who foresee positive impacts over the next two decades. The report also cites Pew Research data showing that 84% of experts believe AI will positively affect medical care, whereas only 44% of the public agrees. Furthermore, 73% of experts are optimistic about AI's impact on employment, contrasting with just 23% of the public. Concerns about AI-driven job losses are prevalent, with 64% of Americans fearing fewer jobs in the future due to AI advancements.
Trendline Trendline
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence

FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence

FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence
Trendline Trendline
IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial
Rapid Read Rapid Read
Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles

Researchers at Oregon State University have developed a novel approach to address two major challenges associated with lung cancer: tumor growth and severe muscle loss. Their study, published in the Journal of Controlled Release, explores the use of lipid nanoparticles to deliver genetic material directly to cancer cells in the lungs. These nanoparticles are engineered to carry follistatin messenger RNA, which instructs cells to produce follistatin, a protein that slows tumor progression and supports muscle growth. The lipid nanoparticles are administered through the bloodstream and are directed to lung cancer tumors by binding with vitronectin, a protein found in blood serum. This method has shown a 2.5-fold greater reduction in tumor burden compared to conventional lipid nanoparticles, which tend to accumulate in the liver.
Trendline Trendline
Biopharma Industry Urged to Align on Data for Effective AI Integration

Biopharma Industry Urged to Align on Data for Effective AI Integration

Biopharma Industry Urged to Align on Data for Effective AI Integration